Requirement for STAT3 and its target, TFCP2L1, in self-renewal of naïve pluripotent stem cells in vivo and in vitro
Biology Open · 2023
DOI: 10.1242/bio.059650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology Open, 2023. Verfasst von Sophie Kraunsoe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge CB…. Hauptthemen laut MEDLINE: Pluripotent Stem Cells, Repressor Proteins, STAT3 Transcription Factor. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Wellcome Trust, University of Cambridge.
Abstract (Originalsprache)
We previously demonstrated gradual loss of epiblast during diapause in embryos lacking components of the LIF/IL6 receptor. Here, we explore the requirement for the downstream signalling transducer andactivator of transcription STAT3 and its target, TFCP2L1, in maintenance of naïve pluripotency. Unlike conventional markers, such as NANOG, which remains high in epiblast until implantation, both STAT3 and TFCP2L1 proteins decline during blastocyst expansion, but intensify in the embryonic region after induction of diapause, as observed visually and confirmed using our image-analysis pipeline, consistent with our previous transcriptional expression data. Embryos lacking STAT3 or TFCP2L1 underwent catastrophic loss of most of the inner cell mass during the first few days of diapause, indicating involvement of signals in addition to LIF/IL6 for sustaining naïve pluripotency in vivo. By blocking MEK/ERK signalling from the morula stage, we could derive embryonic stem cells with high efficiency from STAT3 null embryos, but not those lacking TFCP2L1, suggesting a hitherto unknown additional role for this essential STAT3 target in transition from embryo to embryonic stem cells in vitro. This article has an associated First Person interview with the first author of the paper.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge CB2 0AW, UK.
- Department of Physiology, Development and Neuroscience, University of Cambridge, Tennis Court Road, Cambridge CB2 3EG, UK.
- Department of Biology, University of Padua, Padova 35121, Italy.
- Centre for Trophoblast Research, University of Cambridge, Cambridge, UK.
ORCID-Profile: Sophie Kraunsoe, Takuya Azami, Graziano Martello, Thorsten Boroviak, Jennifer Nichols
Förderung
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- University of Cambridge
- Japan Society for the Promotion of Science
- UEHARA Memorial Foundation
- University of Edinburgh
Zitieren
APA
Kraunsoe, S., Azami, T., Pei, Y., Martello, G., Jones, K., Boroviak, T., & Nichols, J. (2023). Requirement for STAT3 and its target, TFCP2L1, in self-renewal of naïve pluripotent stem cells in vivo and in vitro. Biology Open. https://doi.org/10.1242/bio.059650
Vancouver
Kraunsoe S, Azami T, Pei Y, Martello G, Jones K, Boroviak T, et al. Requirement for STAT3 and its target, TFCP2L1, in self-renewal of naïve pluripotent stem cells in vivo and in vitro. Biology Open. 2023. doi:10.1242/bio.059650
BibTeX
@article{Kraunsoe2023,
author = {Kraunsoe, Sophie and Azami, Takuya and Pei, Yihan and Martello, Graziano and Jones, Kenneth and Boroviak, Thorsten and Nichols, Jennifer},
title = {Requirement for STAT3 and its target, TFCP2L1, in self-renewal of naïve pluripotent stem cells in vivo and in vitro},
journal = {Biology Open},
year = {2023},
doi = {10.1242/bio.059650}
}
EUVIMED